Pharmacological or genetic inhibition of ASCT2 (SLC1A5) has been shown to reduce the growth of gastric cancer (Lu J. et al., 2017), prostate cancer (Wang Q. et al., 2015), and triple-negative breast cancer (Van Geldermalsen et al., 2016). This evidence concerns the gene SLC1A5 and prostate carcinoma.